Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428573 | 1.00 | KDM4E (0.45) | KDM4EGAAALDH1A1POLBNSD2 | |
| SCHEMBL2383543 | 0.88 | KDM4E (0.48) | KDM4EGAAALDH1A1POLBNSD2 | |
| SCHEMBL29693655 | 0.88 | KDM4E (0.48) | KDM4EGAAALDH1A1POLBNSD2 | |
| SCHEMBL589590 | 0.79 | ALDH1A1 (0.45) | KDM4EGAAALDH1A1KHK | |
| SCHEMBL30791197 | 0.79 | KDM4E (0.37) | KDM4EGAAALDH1A1 | |
| SCHEMBL23356128 | 0.79 | KDM4E (0.37) | KDM4EGAAALDH1A1 | |
| SCHEMBL13418145 | 0.79 | KDM4E (0.39) | KDM4EGAANSD2MAPK1 | |
| SCHEMBL13417584 | 0.79 | KDM4E (0.39) | KDM4EGAAALDH1A1POLBKHK | |
| SCHEMBL8139181 | 0.76 | KDM4E (0.42) | KDM4EGAAALDH1A1MAPK1 | |
| SCHEMBL30019671 | 0.76 | KDM4E (0.42) | KDM4EGAAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111978263-B | Preparation method of fampicin and intermediate thereof | 长沙创新药物工业技术研究院有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-10273225-B2 | Pyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-30 | — | — | US | disclosed |
| EP-3105216-B1 | PYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-10 | — | — | EP | disclosed |
| US-20180258073-A1 | PYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2018-09-13 | — | — | US | disclosed |
| US-10000468-B2 | Pyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170174659-A1 | PYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-3105216-A1 | PYRAZINES MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| CN-106103421-A | The pyrazine regulator of GPR6 | 武田药品工业株式会社 | 2016-11-09 | — | — | CN | disclosed |
| WO-2015123533-A1 | PYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000468-B2 | Pyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | KDM4E 3784/4885GAA 2911/4885ALDH1A1 1559/4885 |
| US-20170174659-A1 | PYRAZINES MODULATORS OF GPR6 | GPR6, GPR65, GPR52 | KDM4E 3684/4885GAA 2722/4885ALDH1A1 1522/4885 |
| US-10273225-B2 | Pyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | KDM4E 3784/4885GAA 2911/4885ALDH1A1 1559/4885 |
| US-20180258073-A1 | PYRAZINES MODULATORS OF GPR6 | GPR6, GPR65, GPR52 | KDM4E 3684/4885GAA 2722/4885ALDH1A1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.